30 C
Vientiane
Saturday, May 10, 2025
spot_img
Home Blog Page 652

Moby, a Leading Options Protocol, Expands to Berachain Mainnet

–    Moby’s Strategic Expansion to Scale Institutional-Grade Trading and Structured Products

–    Pioneering Options Innovation: RFA-Selected Moby Enhances Liquidity Berachain’s PoL 

SINGAPORE, Feb. 17, 2025 /PRNewswire/ —  Moby, the No.1 options protocol on Arbitrum with a total trading volume of $3.5 billion, has officially launched on the Berachain Mainnet.

Moby, a Leading Options Protocol, Expands to Berachain Mainnet
Moby, a Leading Options Protocol, Expands to Berachain Mainnet

Berachain is an EVM-identical Layer 1 blockchain that leverages the novel Proof of Liquidity (PoL) consensus mechanism, setting it apart from traditional proof-of-stake (PoS) networks. By embedding liquidity provisioning into its core security model, PoL aligns incentives across validators, applications, and users—ensuring liquidity and security at the network level.

Moby’s pioneering efforts have been recognized through its selection for Berachain’s prestigious Request for Application (RFA) program—an endorsement reflecting the protocol’s robust infrastructure and potential to enhance liquidity across the Berachain ecosystem. Moreover, Moby has secured partnerships with key industry players such as Kodiak, Infrared, PumpBTC and GMX, further solidifying its position within the ecosystem.

Moby offers two key advantages for Berachain traders and institutions: deeper liquidity and exceptionally tight spreads, both designed to ensure an optimal trading environment. Meanwhile, liquidity providers benefit from high passive income, underpinned by stable risk management achieved through real-time automatic hedging.

Additionally, Moby’s Structured Product Vault (SPV) seamlessly integrates with Berachain’s PoL mechanism, providing an efficient yield-enhancing solution. The SPV aggregates PoL rewards and optimizes their yield through algorithmic options trading. It will integrate LST/LRT and Real World Assets (RWA) to expand the on-chain options market.

“The expansion to Berachain is a pivotal step for Moby,” stated Ben, CEO of Moby. “By leveraging Berachain’s PoL model, we are setting the stage for a more liquid and scalable on-chain options market—ushering in a new era of institutional-grade trading and structured products”

Coinciding with its official launch on the Berachain mainnet, Moby introduced an incentive program for early access users. This initiative allows users to earn rewards based on their engagement.

Moby Contacts

Team Moby
team@moby.trade

About Moby

Moby is an on-chain options protocol to lead the next narrative for DeFi. Moby offers an optimized trading environment based on its pioneering SLE (Synchronized Liquidity Engine) and Dynamic Risk Premium model, which enables real-time accurate pricing, narrowest spread in the market, abundant liquidity, and Robinhood-class UI/UX.

Moby is set to provide new features such as capital efficiency improvement models and structured products to welcome institutions and the traditional TradFi audience.

 Website  Twitter  Discord  Docs  Blog  Telegram

Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, Feb. 17, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that its first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, IBI363, has received its second Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). This designation applies to the treatment of unresectable, locally advanced, or metastatic squamous non-small cell lung cancer (sqNSCLC) that has progressed following anti-PD-(L)1 immune checkpoint inhibitor therapy and platinum-based chemotherapy. IBI363 has demonstrated encouraging efficacy and safety across multiple solid tumor types. Currently, Innovent is conducting Phase 1/2 clinical trials of IBI363 mainly in China and the U.S.

At the World Conference on Lung Cancer (WCLC) in September 2024, IBI363 presented promising efficacy signals in patients with sqNSCLC who had previously received immunotherapy:

  • In the 3 mg/kg dose group, among patients with at least 12 weeks of follow-up or study completion (n=18), the objective response rate (ORR) was 50.0%, and the disease control rate (DCR) was 88.9%. The median progression-free survival (PFS) has not yet been reached and remains under follow-up.
  • In the 1/1.5 mg/kg dose group, the median PFS was 5.5 months (95% CI: 1.5, 8.3), with a 12-month PFS rate of 30.7%, highlighting the potential long-term benefits of immunotherapy.
  • Across the 1/1.5/3 mg/kg dose groups, patients with PD-L1 TPS<1% (n=22) and those with PD-L1 TPS≥1% (n=22) achieved encouraging ORRs of 36.4% and 31.8%, respectively, suggesting IBI363's potential advantage in PD-L1 low-expression populations.

Dr. Hui Zhou, Senior Vice President of Innovent, stated, “We are pleased that IBI363 has been granted Fast Track Designation by the FDA for sqNSCLC, following its previous designation for melanoma. Earlier, we reported that in an expanded cohort of sqNSCLC patients, IBI363 showed a trend toward improved ORR and DCR at higher doses, along with a manageable safety profile. The latest PFS data from the 3 mg/kg dose group after longer follow-up further strengthens our confidence in IBI363’s potential as an immunotherapy offering long-term benefits to patients. We will present the relevant data at upcoming academic conferences this year. More encouragingly, IBI363 has demonstrated potent anti-tumor activity regardless of PD-L1 expression levels. This suggests that IBI363 may not only advance treatment for immunotherapy-resistant populations but also for cold tumors with low or no PD-L1 expression. In addition to lung cancer, we have observed encouraging efficacy signals in cold tumors, including colorectal cancer and mucosal melanoma, with melanoma already advancing to pivotal clinical stages. Moving forward, we will continue to explore IBI363 in early-line treatment and in combination therapies.”

Fast Track Designation (FTD) is a regulatory process designed to expedite the clinical development and review of drugs intended to treat serious conditions and address unmet medical needs. Drug candidates granted FTD benefit from increased communication with the FDA throughout subsequent drug development, potentially accelerating their clinical development and approval process.

About IBI363 (First-in-class PD-1/IL-2α-bias bispecific antibody fusion protein))

IBI363 is a first-in-class drug candidate independently developed by Innovent Biologics. It is a PD-1/IL-2 bispecific antibody fusion protein designed to enhance efficiency while minimizing toxicity. The IL-2 arm of IBI363 has been engineered to optimize therapeutic effects with reduced side effects, while the PD-1 binding arm enables PD-1 blockade and selective IL-2 delivery. By simultaneously inhibiting the PD-1/PD-L1 pathway and activating the IL-2 pathway, IBI363 facilitates more precise and efficient targeting and activation of tumor specific T cells. Preclinical studies have shown that IBI363 exhibits strong anti-tumor activity across multiple tumor-bearing pharmacological models, including those resistant to PD-1 inhibitors and metastatic models. Additionally, it has demonstrated a favorable safety profile in preclinical models. Clinical trials are currently underway in China, the United States, and Australia to evaluate its safety, tolerability and preliminary efficacy in subjects with advanced malignancies.

About Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Lung cancer is the most common and deadliest malignancy worldwide, including in China[1], posing a significant public health challenge. Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancer cases[2], with squamous cell carcinoma being one of its two major subtypes[2]. In recent years, immune checkpoint inhibitors have transformed the treatment landscape for NSCLC. However, for patients with NSCLC who have failed immunotherapy and lack driver gene mutations, there remains a significant and urgent unmet need for effective treatment options. The standard second- or third-line treatment, docetaxel, offers limited efficacy, with a median progression-free survival (PFS) of less than four months[3],[4]. While antibody-drug conjugates (ADCs) have shown promise, two large Phase 3 studies in squamous NSCLC have yet to demonstrate satisfactory efficacy[3],[4].

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 14 products in the market. It has 3 new drug applications (NDA) under regulatory review, 3 assets in Phase III or pivotal clinical trials and 17 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

References:

1 Globocan 2022 (version 1.1) – 08.02.2024

2 NCCN guidelines (NSCLC, version 3.2025)

3 J Clin Oncol . 2025 Jan 20;43(3):260-272. doi: 10.1200/JCO-24-01544.

4 J Clin Oncol . 2024 Aug 20;42(24):2860-2872. doi: 10.1200/JCO.24.00733.

 

EcoFlow Launches DELTA 3 Plus and RIVER 3 Plus in Australia

SYDNEY, Feb. 17, 2025 /PRNewswire/ — EcoFlow is introducing two new portable power solutions, designed to give Australians flexible, innovative and reliable energy for every situation. The EcoFlow DELTA 3 Plus is a dependable home power backup solution that you can also take anywhere, from RVs and caravans to tents and outdoor adventures. The EcoFlow RIVER 3 Plus is a lightweight, easy-to-carry power station built for entry-level users who need a steady source of power while camping, on road trips, or driving across the country. With a simple design and consistent powerful performance, these new solutions ensure Australians stay powered.

As Australians embrace the outdoors more than ever – taking over 15 million caravan and camping trips in 2023 – and with extreme weather events causing more frequent power outages, the need for available, portable power has never been greater. Whether preparing for blackouts due to the forces of mother nature, or staying powered off-grid, EcoFlow’s new products offer flexible energy solutions to meet the needs of Australians today.

Key product features:

EcoFlow DELTA 3 Plus:

Fast charging, powerful output and worry-free endurance. EcoFlow DELTA 3 is a reliable home power backup solution.
Fast charging, powerful output and worry-free endurance. EcoFlow DELTA 3 is a reliable home power backup solution.

  • Fast charging with a capacity of 1024kWH and 1800W output. For example, a 30-minute charge from an AC wall socket can provide enough backup power for a typical refrigerator for at least five hours.
  • Powerful output and ultra-quiet operation. With 11 outport ports, it can continuously power appliances up to 2400W, such as ovens, hair dryers and kettles – perfect for RVs, 4WD trips and home backup power. It runs quietly at just 30db; when using less than 600W, it blends into the background, making it virtually unnoticeable – ideal for use in a tent without disturbing sleep.
  • Compact design and portable. It is more portable compared to its predecessor, weighing 12.5kg. The weight is approximately equal to that of a family tent for two to three people.

EcoFlow RIVER 3 Plus:

Compact, 10ms professional uninterrupted power supply and fast charging. The EcoFlow RIVER 3 Plus is built for entry-level users.
Compact, 10ms professional uninterrupted power supply and fast charging. The EcoFlow RIVER 3 Plus is built for entry-level users.

  • Compact and long-lasting runtime. Weighing only 4.7kg, it is designed to be taken anywhere that needs quick and reliable power. It also offers a 286Wh capacity, which can power your Wi-Fi router up to 35 hours.
  • Fast-charging with multiple charging methods. Traditional home UPS batteries often take eight hours or more to recharge and usually only support AC charging. With its fast charge technology, it significantly reduces AC charging time to just one hour, without damaging the battery. It also supports many charging options, including solar, car and generator.
  • 10ms UPS capability. In an event of a power outage, it can prevent issues like food spoilage from fridge shutdowns, or data loss from sudden computer failures, ensuring essential devices stay powered without interruption.

Both the EcoFlow DELTA 3 Plus and EcoFlow RIVER 3 Plus are available from today via the EcoFlow Australia website, eBay Australia and Amazon Australia.  

The EcoFlow DELTA 3 Plus is $1,599 and the EcoFlow RIVER 3 Plus is $499.

Earlier this month, EcoFlow also launched EcoFlow RIVER 3 (UPS). Its ultra-fast UPS makes it the perfect companion for outdoor adventures.

Images and more information can be found in the below respective media kits.  

About EcoFlow 

EcoFlow is a leading provider of eco-friendly energy solutions, committed to powering a new world. Since its founding in 2017, EcoFlow has aimed to be the FIRST in power solutions — Flexible, Innovative, Reliable, Simple, and Thorough — for individuals and families, whether at home, outdoors or on the go. With a smart manufacturing center in China, and headquarters in the USA, Germany and Japan, EcoFlow has empowered over 4.5 million users in 140 markets worldwide. For more information, visit https://www.ecoflow.com/au

Media Contact
Allison Worldwide for EcoFlow Australia 
ecoflowanz@allisonworldwide.com  

Navi Medical Technologies’ Neonav® ECG Tip Location System Receives FDA 510(k) Clearance

Revolutionising Vascular Access Care for Critically Ill Newborns and Children

Key Points:

  • FDA 510(k) Clearance Neonav® ECG Tip Location System is now FDA-cleared, enabling its use in U.S. hospitals to enhance pediatric vascular access care.
  • First-of-its-kind Innovation: Neonav® is the only system designed specifically for neonatal and pediatric patients, using real-time ECG signal analysis to ensure accurate placement of Central Venous Access Devices (CVADs), significantly reducing risks like misplacement and migration.
  • U.S. Market Expansion: With clearance secured, and offices in Australia and the United States, Navi Medical Technologies plans to raise capital and engage hospital networks to bring Neonav® to U.S. healthcare providers.
  • Australian Innovation on the Global Stage: Based in Melbourne, Navi is demonstrating how Australian medtech can revolutionize global pediatric care.

MELBOURNE, Australia, Feb. 17, 2025 /PRNewswire/ — Navi Medical Technologies, a medical device company focused on pediatric healthcare innovation, proudly announces that its Neonav® ECG Tip Location System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

This milestone represents a significant step forward in vascular access care for critically ill newborns and children worldwide. The Neonav® is the first medical device of its kind specifically designed for neonatal and pediatric care. By using real-time ECG signal analysis, it aids accurate placement of Central Venous Access Devices (CVADs), significantly reducing the risks associated with misplacement and migration which can cost US hospitals up to USD$1 Billion per year. This breakthrough innovation minimises reliance on confirmatory chest X-rays, will help in reducing delays in care, as well as lowering unintended complications for vulnerable patients.

World-First Technology Tailored for Pediatric Patients

The Neonav® system has the broadest ‘Indication For Use’ of any tip location system on the market, covering preterm newborns through to adults. Importantly, the system can be used to place tiny 1Fr catheters used in very small newborns, and is cleared for placement of catheters both above and below the heart. The system has also been developed to enable ongoing surveillance of catheters after the initial placement, an important first which can help to prevent potentially serious healthcare complications resulting from undiagnosed movement of the tip of the catheter. These novel features address critical challenges faced by healthcare professionals in neonatal and pediatric care.

Dr Janene Fuerch is a Neonatologist at Stanford Children’s Health, and is excited about the prospect of the Neonav being available to assist with the treatment of  children in the United States, “Central lines are lifesaving but can be challenging to position. We need a guidance system to tell us when we are in the correct location. The Neonav system fulfills that need and gives a characteristically blind procedure a way to move forward, telling you exactly where you are and how to move into the correct position”

Strategic Growth & U.S. Expansion

With FDA clearance secured, and offices in Australian and the United States, Navi Medical Technologies will seek to raise capital later this year to support its entry into the U.S. market, “We recognize the tremendous opportunity to bring our ground-breaking technology to the U.S., and we will continue to engage hospital networks and potential partners that can help ensure that our innovations reach the patients who need them most” said Alex Newton, CEO of Navi.

“With FDA clearance in hand, we’re uniquely positioned to drive significant impact in the largest healthcare market in the world. Our investors have the chance to be part of a mission that’s not only financially rewarding but also deeply meaningful. By working together, we can ensure that every critically ill child has access to safer, faster, and more effective care.”

Backed by Leading Healthcare Innovators & Partners

Navi Medical Technologies acknowledges the invaluable support of its investors and partners, including Breakthrough Victoria, The Royal Women’s Hospital, the Australian Federal and Victorian Governments, MTPConnect, and the US FDA Pediatric Device Consortia program. Their backing has been instrumental in achieving this milestone and advancing Navi’s mission to improve pediatric healthcare worldwide.

“We wouldn’t be here without the backing of our investors and partners,” said Alex. “Their support and belief in our vision has enabled us to reach this point and set the stage for global expansion. We’re deeply grateful for their ongoing commitment to innovation and healthcare improvement.”

An Australian Success Story

The FDA clearance highlights Australia’s thriving medtech sector. Minister for Economic Growth and Jobs Danny Pearson celebrated the achievement:

“This local Victorian company will be taking its home-grown technology to the United States – helping make hospital care safer for critically ill newborn babies on the other side of the world.”

Victoria is the medical research capital of Australia – this is a booming industry that is backing economic growth and quality advanced manufacturing jobs across our state.”

Breakthrough Victoria, an investor in Navi, also praised the company’s progress. CEO Rod Bristow commented: “As an investor, we are excited about Navi’s trajectory and its potential to become a leader in the paediatric medical device market. With strong fundamentals, regulatory validation, and a clear pathway to commercialisation, Navi represents a compelling investment opportunity with both financial and wider societal impact.”

About Navi Medical Technologies

Navi Medical Technologies is a Melbourne-based medtech company dedicated to advancing pediatric healthcare. By collaborating with leading clinicians, Navi develops breakthrough technologies that improve outcomes for the most vulnerable patients.

Email: info@navitechnologies.com 
Website: www.navitechnologies.com

Documentary A Bite of China (Season 4) Sparks Discussion: Cultural Ripples from Culinary Encounters

BEIJING, CHINA – Media OutReach Newswire – 15 February 2025 – Cultural exchange has become an essential bridge for communication between nations. Recently, products associated with China, such as the AI technology DeepSeek, the animated film Ne Zha 2, and the food documentary A Bite of China (Season 4), have converged to create a powerful wave of “Chinese style” that is making waves across the globe. Among these, A Bite of China (Season 4) has opened the taste buds of global audiences, allowing them to explore Chinese culture through the universal topic of food. As the documentary gains popularity, a series of visually stunning short videos have gone viral on major social media platforms, attracting media attention and coverage from countries and regions including Portugal, Canada, Japan, South Korea, South Africa, Italy, Dubai, Greece, and Peru.

For a long time, Chinese cuisine abroad has been stereotyped as “convenient,” “takeout,” and “sweet and sour.” However, A Bite of China (Season 4) uses exquisite cinematography to reveal the rich stories and Eastern philosophy behind Chinese food. From its journey across the seas to local adaptations and deep integration with foreign cuisines, Chinese food has sparked cultural ripples, blending and merging with other culinary traditions worldwide.

One particularly striking scene in the documentary shows a street in Paris, where blonde-haired, blue-eyed diners shout “Dao Xiao Mian” (knife-cut noodles) in Chinese. Meanwhile, a Chinese woman in a food truck skillfully slices dough into leaf-like noodles with a curved knife, dropping them into a bubbling pot. This traditional Chinese noodle dish, with its “Chinese kung fu” of kneading and resting, allows French diners to experience authentic Eastern craftsmanship passed down through millennia. One viewer commented on social media, “Watching Chinese chefs cook is like watching a spectacular performance; their hands seem magical, transforming ordinary ingredients into delicious dishes in no time.”

In addition to the authentic journey of Chinese cuisine, Chinese food culture is taking root in various corners of the world, blending and coexisting with local culinary traditions. Southeast Asia’s Nyonya cuisine reflects the wisdom and aesthetic of Chinese dining, with each flavor echoing the Chinese community’s longing for the tastes of their homeland. Michelin-starred chef Adeline in France showcases her “Sino-French fusion” philosophy by using a Chinese wok to prepare the famous French dish bouillabaisse, replacing frying pans with steamers for foie gras, and incorporating Shaoxing wine, a Chinese flower wine, into a white sauce. She also uses Zhenjiang vinegar paired with cinnamon to create a black vinegar sauce. Familiar ingredients, yet unfamiliar flavors, allow French diners to enjoy a delightful culinary experience.

As the world collectively celebrates the first Spring Festival following its successful application for UNESCO recognition, the popularity of A Bite of China (Season 4) is ushering in a new wave of global interest in Chinese cuisine. Foreign viewers are experiencing the vibrant atmosphere of the Spring Festival and the diversity of Chinese food culture, with comments such as, “I used to only know General Tso’s chicken and Mapo tofu, but after watching the documentary, I realized how vast the world of Chinese cuisine is. I want to visit a Chinese restaurant during the Spring Festival to try more delicious dishes.”

The fusion of Chinese and foreign cuisines is not limited to restaurants; it has also permeated the daily lives of ordinary people. In traditional markets in France, Chinese vinegar is displayed alongside Italian balsamic vinegar; in various Southeast Asian countries, Chinese restaurants are transforming from “exclusive to Chinese” to “national cuisine”; in American classrooms, Chinese cuisine has become a subject for global students to understand and learn.

At the same time, China is welcoming the world with a more open attitude. Recent visa facilitation policies for foreigners have made it fashionable to “check in” on Chinese customs and traditions. The airing of A Bite of China (Season 4) will undoubtedly spark more interest among foreigners in Chinese cuisine, encouraging them to experience this land firsthand—tasting freshly made jianbing (Chinese crepes) in the alleys, savoring West Lake vinegar fish in the waters of Jiangnan, and feeling the heat of spicy hotpot in the streets of Sichuan and Chongqing.

As the documentary states, “If there truly exists a clear culinary map of the world, it certainly would not have clear national borders.” When French diners pick up knife-cut noodles with chopsticks, when Silicon Valley elites have Shanghai wontons on their plates, and when the British public falls in love with “spicy” and “fish fragrant” flavors, they are not just tasting a symphony created by Chinese cooking techniques; they are experiencing the passion of an ancient civilization for life.

Hashtag: #ABiteofChina

The issuer is solely responsible for the content of this announcement.

Vantage Honored with Three Prestigious Awards at the 5th Annual Business Tabloid Awards

PORT VILA, Vanuatu, Feb. 15, 2025 /PRNewswire/ — Vantage Markets is proud to announce its success at the 5th Annual Business Tabloid Awards, held on 23rd January 2025 in Dubai. The Annual Business Tabloid Awards celebrate outstanding achievements across industries, including banking, finance, technology, and leadership. Winners are selected by a panel of industry experts, who evaluate nominees based on innovation, performance, and impact. Receiving three awards at this distinguished event reflects Vantage’s global commitment to excellence in the financial services industry.

Vantage Wins Big at the 5th Annual Business Tabloid Awards
Vantage Wins Big at the 5th Annual Business Tabloid Awards

  • Best CFD Broker – APAC: This award reflects Vantage’s leadership in providing advanced tools, competitive pricing, and tailored solutions for traders.
  • Best Value Broker – LATAM: Vantage’s dedication to delivering cost-effective trading solutions while maintaining exceptional quality earned it this distinction.
  • Best Trading Platform – MENA: This recognition underscores Vantage’s investment in cutting-edge technology and its commitment to meeting the unique needs of traders.

Vantage Wins Big at the 5th Annual Business Tabloid Awards
Vantage Wins Big at the 5th Annual Business Tabloid Awards

The event brought together industry leaders and influencers to celebrate excellence across various sectors, including banking, finance, technology, and trading. The evening commenced with a networking session, providing an invaluable opportunity for professionals to connect and exchange insights. Followed by the award presentation ceremony, where Vantage was honored for its excellence, reflecting its commitment to providing quality trading solutions.

Marc Despallieres, CEO of Vantage Markets, shared his thoughts on the achievement: “Winning these three awards at the Business Tabloid Awards is a testament to our commitment to excellence, innovation, and client-centricity. These accolades reflect the hard work of our team and the trust our clients place in us. We are proud to have been recognized for our excellence in APAC, LATAM, and MENA, reflecting our commitment to empowering our traders.”

As Vantage continues to expand its presence and deliver value to its clients, the company is committed to maintaining its reputation for excellence and innovation.

For more information on Vantage’s award-winning services, visit Vantage Markets.

About Vantage

Vantage Markets (or Vantage) is a multi-asset CFD broker offering clients access to a nimble and powerful service for trading Contracts for Difference (CFDs) products, including Forex, Commodities, Indices, Shares, ETFs, and Bonds.

With over 15 years of market experience, Vantage transcends the role of broker, providing a trusted trading ecosystem, an award-winning mobile trading app, and a user-friendly trading platform that empowers clients to seize trading opportunities. Download the Vantage App on App Store or Google Play.

trade smarter @vantage

Important Notice: This article is for informational purposes only and does not constitute an offer or solicitation of Vantage’s services in any jurisdiction. Vantage’s services may not be available in all regions mentioned and are subject to strict regulatory requirements. Before engaging with our services, please check your local regulations to ensure you are eligible to access our products and services in your region.

RISK WARNING: CFD trading carries significant risks. You could lose more than your initial investment.

SCIA boosts global ventures of Chinese enterprises

BEIJING, Feb. 15, 2025 /PRNewswire/ — A news report from chinadaily.com.cn:

View of 2025 SCIA Spring Reception.
View of 2025 SCIA Spring Reception.

As the global influence of the Guangdong-Hong Kong-Macao Greater Bay Area in arbitration continues to grow, the Shenzhen Court of International Arbitration, or SCIA, is supporting Chinese business enterprises in their global ventures.

It’s also contributing to international trade and economic exchanges, according to industry experts and corporate representatives at a dialogue held on Feb 12 in Shenzhen, South China’s Guangdong province.

SCIA council members from Hong Kong, Macao and overseas, along with over 50 representatives from major Chinese companies, discussed global economic trends, challenges and opportunities for Chinese enterprises.

They highlighted the crucial role of international arbitration in resolving disputes in trade, investment, finance and maritime commerce. 

Liu Xiaochun, SCIA president and executive chairman of the South China International Arbitration Center (HK), stressed the importance of leveraging international rules and Hong Kong and Macao’s strengths to protect the rights of Chinese enterprises overseas.

“We need to build a stable, transparent, fair and predictable market-oriented, rule-of-law and international business environment,” he said. 

Under the framework of “one country, two systems and three legal jurisdictions”, the SCIA aligns rules with Hong Kong and Macao to facilitate business in common law and Portuguese-speaking countries.

Liu noted that Hong Kong’s resources connected SCIA to common law countries, while Macao’s unique legal system strengthened links to Portuguese and Spanish-speaking nations – providing professional and transparent dispute resolution services for Chinese enterprises. 

Roberto Azevêdo, SCIA council member and former director-general of the World Trade Organization, underscored that international dispute resolutions provided stability to global trade relations. He said that the SCIA played a vital role in ensuring robust mechanisms for resolving international commercial disputes.

Anthony Neoh, SCIA vice-chairman, highlighted the council’s international composition – including experts in China, from Hong Kong and Macao – which enhanced confidence in its legal and arbitration systems. 

“We are connected with judicial institutions in Shenzhen, Hong Kong and Macao. The courts and arbitration institutions across these three regions are organically integrated, enhancing confidence in our legal and arbitration systems,” Neoh added.

To better serve Chinese and foreign clients and meet the demand for risk prevention and dispute resolution in the international operations of enterprises, the SCIA continues to promote its international development.

In 2024, it accepted a record 14,518 commercial arbitration cases, with the total disputed amount reaching 142.27 billion yuan ($19.67 billion) – maintaining its position among the top three arbitration institutions globally.

The number of newly accepted international commercial arbitration cases rose to 520, a whopping year-on-year increase of 25.6 percent. Meanwhile, the geographic coverage of global clients expanded further, with parties from 64 countries and regions involved, representing a 45 percent year-on-year increase.

To date, the SCIA has served parties from a cumulative 142 countries and regions. Of its 2,087 arbitrators, currently, 733 are from overseas, accounting for 35.12 percent of the total.

HYPTEC HT Tops the Best-selling List of High-end Pure Electric SUV in Thailand for Two Consecutive Months

BEIJING, Feb. 15, 2025 /PRNewswire/ — The latest monthly sales data from Thailand show that HYPTEC HT, a premium model from the Chinese EV brand GAC HYPTEC, has become the best-selling high-end pure electric SUV in the Thai market for two months in a row.


As one of the most proactive countries in Southeast Asia when it comes to promoting electric vehicles, Thailand has seen a surge of Chinese EV brands entering the market in recent years, with GAC HYPTEC as a strong contender. The HYPTEC HT, with its all-encompassing premium features, has quickly become a sought-after “new luxury” vehicle among Thailand’s elites. The vehicle received widespread attention when it was officially delivered to Thai celebrity Thassapak Hsu (Bie) in October 2024, further solidifying its popularity.

Boasting a 2,935 mm wheelbase, striking gullwing doors, and a range of luxury features, including NAPPA leather upholstery across all variants, the HYPTEC HT offers a new level of intelligent luxury for families worldwide.


As global demand for electric vehicles continues to rise, Chinese NEV brands are among the first to make significant breakthroughs in the Thai market, with steady growth in sales figures. This success can be attributed to a keen understanding of the local market and in-depth insights into overseas consumers. GAC HYPTEC remains committed to its core values of “Technology, Luxury, and Classy” while prioritizing a user-centric approach. By staying focused on these guiding principles, GAC HYPTEC aims to drive its global expansion, turning the technological edge of Chinese EV brands into a distinct market advantage, helping them shine on the global automotive stage.